Shopping Cart
- Remove All
- Your shopping cart is currently empty
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $463 | In Stock | |
10 mg | $742 | In Stock | |
25 mg | $1,120 | In Stock | |
50 mg | $1,490 | In Stock |
Description | Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL). |
Targets&IC50 | Daudi cell lines:0.08-0.09 μg/mL (EC50) |
In vitro | Veltuzumab was effective in reducing dissociation rates in human lymphoma cell lines and enhancing complement-dependent cytotoxicity in 1 of 3 cell lines, but did not exhibit other significant in vitro differences. [1] Veltuzumab (0.001-10 μg/mL, 3 hours) had low EC50 values ranging from 0.08-0.09 μg/mL in Daudi cell lines. [1] |
In vivo | Veltuzumab (intravenous or subcutaneous; 5, 20, and 60 μg; single dose) achieves control of tumor growth, or removal of circulating and adherent B cells, at low doses in mouse models. [1] Veltuzumab (intraperitoneal; 0.05-35 μg) demonstrated significant efficacy in in vivo studies. [1] |
Alias | IMMU-106, IMMU106, hA20 |
Cas No. | 728917-18-8 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.